Jiangzhong Pharmaceutical Co Ltd

SHG:600750 China Drug Manufacturers - Specialty & Generic
Market Cap
$2.19 Billion
CN¥16.08 Billion CNY
Market Cap Rank
#6546 Global
#1007 in China
Share Price
CN¥25.30
Change (1 day)
-0.90%
52-Week Range
CN¥21.21 - CN¥25.77
All Time High
CN¥561.13
Categories
Companies in China Drug Manufacturers - Specialty & Generic
About

China Resources Jiangzhong Pharmaceutical Co.,Ltd engages in the manufacture of pharmaceutical products in China. The company offers OTC products, including stomach-strengthening and digestion-promoting tablets, lactobacillus tablets, triple live bifidobacterium enteric-coated capsules, compound fresh bamboo juice liquid, compound coral lozenges, multivitamin tablets, Fritillaria and loquat capsu… Read more

Jiangzhong Pharmaceutical Co Ltd (600750) - Net Assets

Latest net assets as of September 2025: CN¥4.45 Billion CNY

Based on the latest financial reports, Jiangzhong Pharmaceutical Co Ltd (600750) has net assets worth CN¥4.45 Billion CNY as of September 2025.

Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (CN¥6.89 Billion) and total liabilities (CN¥2.44 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.

Key Net Assets Metrics

Metric Value
Current Net Assets CN¥4.45 Billion
% of Total Assets 64.54%
Annual Growth Rate 17.31%
5-Year Change 5.18%
10-Year Change 89.91%
Growth Volatility 85.91

Jiangzhong Pharmaceutical Co Ltd - Net Assets Trend (1993–2024)

This chart illustrates how Jiangzhong Pharmaceutical Co Ltd's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.

Annual Net Assets for Jiangzhong Pharmaceutical Co Ltd (1993–2024)

The table below shows the annual net assets of Jiangzhong Pharmaceutical Co Ltd from 1993 to 2024.

Year Net Assets Change
2024-12-31 CN¥4.47 Billion -0.08%
2023-12-31 CN¥4.48 Billion -0.45%
2022-12-31 CN¥4.50 Billion -1.90%
2021-12-31 CN¥4.58 Billion +7.79%
2020-12-31 CN¥4.25 Billion +8.33%
2019-12-31 CN¥3.92 Billion +20.62%
2018-12-31 CN¥3.25 Billion +11.60%
2017-12-31 CN¥2.92 Billion +11.45%
2016-12-31 CN¥2.62 Billion +11.09%
2015-12-31 CN¥2.35 Billion +10.38%
2014-12-31 CN¥2.13 Billion -0.01%
2013-12-31 CN¥2.13 Billion +3.90%
2012-12-31 CN¥2.05 Billion +7.06%
2011-12-31 CN¥1.92 Billion +7.79%
2010-12-31 CN¥1.78 Billion +65.82%
2009-12-31 CN¥1.07 Billion +10.68%
2008-12-31 CN¥969.41 Million +15.69%
2007-12-31 CN¥837.97 Million +11.93%
2006-12-31 CN¥748.62 Million +6.62%
2005-12-31 CN¥702.13 Million +5.93%
2004-12-31 CN¥662.81 Million +3.60%
2003-12-31 CN¥639.80 Million +11.23%
2002-12-31 CN¥575.21 Million +4.38%
2001-12-31 CN¥551.04 Million +0.97%
2000-12-31 CN¥545.76 Million +5.75%
1999-12-31 CN¥516.08 Million +85.73%
1998-12-31 CN¥277.86 Million +13.20%
1997-12-31 CN¥245.46 Million +11.89%
1996-12-31 CN¥219.37 Million +488.19%
1995-12-31 CN¥37.30 Million +8.55%
1994-12-31 CN¥34.36 Million +8.53%
1993-12-31 CN¥31.66 Million --

Equity Component Analysis

This analysis shows how different components contribute to Jiangzhong Pharmaceutical Co Ltd's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.

Equity Composition Insights

  • Retained earnings have grown by 249174655000.0% over the analyzed period, indicating profitable operations and earnings retention.

Current Equity Component Breakdown (December 2024)

Component Amount Percentage
Retained Earnings CN¥2.49 Billion 64.51%
Common Stock CN¥629.02 Million 16.28%
Other Comprehensive Income CN¥433.58 Million 11.22%
Other Components CN¥308.46 Million 7.99%
Total Equity CN¥3.86 Billion 100.00%

Jiangzhong Pharmaceutical Co Ltd Competitors by Market Cap

The table below lists competitors of Jiangzhong Pharmaceutical Co Ltd ranked by their market capitalization.

Company Market Cap
Hubei Jumpcan Pharmaceutical Co Ltd
SHG:600566
 		$1.21 Billion
Bitfarms Ltd
NASDAQ:BITF
 		$1.21 Billion
Chengdu Xingrong Investment Co Ltd
SHE:000598
 		$1.21 Billion
STORSKOGEN GROUP AB SER.B
F:0VK
 		$1.21 Billion
City Developments Ltd
PINK:CDEVY
 		$1.21 Billion
Ningbo Boway Alloy Material Co Ltd
SHG:601137
 		$1.21 Billion
Seaboard Corporation
NYSE MKT:SEB
 		$1.21 Billion
CLARIVATE PLC
NYSE:CLVT
 		$1.21 Billion

Equity Growth Attribution

This analysis shows how different factors contributed to changes in Jiangzhong Pharmaceutical Co Ltd's equity between the two most recent reporting periods.

Equity Growth Insights

  • From 2023 to 2024, total equity changed from 3,831,520,111 to 3,862,808,649, a change of 31,288,538 (0.8%).
  • Net income of 788,192,565 contributed positively to equity growth.
  • Dividend payments of 768,458,565 reduced retained earnings.
  • Share repurchases of 1,307,931 reduced equity.
  • Other comprehensive income increased equity by 166,447.

Equity Change Factors (2023 to 2024)

Factor Impact Contribution
Net Income CN¥788.19 Million +20.4%
Dividends Paid CN¥768.46 Million -19.89%
Share Repurchases CN¥1.31 Million -0.03%
Other Comprehensive Income CN¥166.45K +0.0%
Other Changes CN¥12.70 Million +0.33%
Total Change CN¥- 0.82%

Book Value vs Market Value Analysis

This analysis compares Jiangzhong Pharmaceutical Co Ltd's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.

Valuation Insights

  • Current price-to-book ratio: 4.13x
  • The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
  • The price-to-book ratio has decreased from 419.60x to 4.13x over the analyzed period, indicating reduced market premium.

Historical Price-to-Book Ratios

Date Book Value per Share Market Price P/B Ratio
1993-12-31 CN¥0.06 CN¥25.30 x
1994-12-31 CN¥0.07 CN¥25.30 x
1995-12-31 CN¥0.07 CN¥25.30 x
1996-12-31 CN¥0.42 CN¥25.30 x
1997-12-31 CN¥0.47 CN¥25.30 x
1998-12-31 CN¥0.53 CN¥25.30 x
1999-12-31 CN¥0.98 CN¥25.30 x
2000-12-31 CN¥1.00 CN¥25.30 x
2001-12-31 CN¥1.00 CN¥25.30 x
2002-12-31 CN¥1.05 CN¥25.30 x
2003-12-31 CN¥1.15 CN¥25.30 x
2004-12-31 CN¥1.26 CN¥25.30 x
2005-12-31 CN¥1.33 CN¥25.30 x
2006-12-31 CN¥1.22 CN¥25.30 x
2007-12-31 CN¥1.35 CN¥25.30 x
2008-12-31 CN¥1.49 CN¥25.30 x
2009-12-31 CN¥1.65 CN¥25.30 x
2010-12-31 CN¥2.78 CN¥25.30 x
2011-12-31 CN¥2.85 CN¥25.30 x
2012-12-31 CN¥3.04 CN¥25.30 x
2013-12-31 CN¥3.16 CN¥25.30 x
2014-12-31 CN¥3.25 CN¥25.30 x
2015-12-31 CN¥3.73 CN¥25.30 x
2016-12-31 CN¥4.17 CN¥25.30 x
2017-12-31 CN¥4.61 CN¥25.30 x
2018-12-31 CN¥5.19 CN¥25.30 x
2019-12-31 CN¥5.65 CN¥25.30 x
2020-12-31 CN¥6.15 CN¥25.30 x
2021-12-31 CN¥6.33 CN¥25.30 x
2022-12-31 CN¥6.24 CN¥25.30 x
2023-12-31 CN¥6.06 CN¥25.30 x
2024-12-31 CN¥6.13 CN¥25.30 x

Capital Efficiency Dashboard

This dashboard shows how efficiently Jiangzhong Pharmaceutical Co Ltd utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.

Capital Efficiency Insights

  • Current Return on Equity (ROE): 20.40%
  • The company demonstrates strong efficiency in generating profits from shareholder equity.
  • DuPont Analysis Breakdown:
  • • Net Profit Margin: 17.77%
  • • Asset Turnover: 0.68x
  • • Equity Multiplier: 1.68x
  • Recent ROE (20.40%) is above the historical average (15.11%), indicating improving capital efficiency.

Historical Capital Efficiency Metrics

Year Return on Equity Net Profit Margin Asset Turnover Equity Multiplier Economic Value Added
1993 59.03% 8.74% 2.82x 2.40x CN¥15.52 Million
1994 39.29% 5.75% 2.82x 2.42x CN¥10.06 Million
1995 39.40% 4.35% 3.14x 2.89x CN¥10.97 Million
1996 11.81% 11.18% 0.72x 1.48x CN¥3.97 Million
1997 10.30% 11.56% 0.53x 1.68x CN¥736.95K
1998 11.19% 16.81% 0.44x 1.52x CN¥3.30 Million
1999 5.66% 22.47% 0.19x 1.31x CN¥-22.38 Million
2000 0.11% 0.15% 0.52x 1.35x CN¥-51.76 Million
2001 7.22% 10.65% 0.56x 1.22x CN¥-14.54 Million
2002 7.86% 6.47% 0.90x 1.35x CN¥-11.76 Million
2003 8.42% 5.39% 0.95x 1.64x CN¥-9.49 Million
2004 6.53% 5.17% 0.72x 1.76x CN¥-22.89 Million
2005 7.66% 5.48% 0.85x 1.64x CN¥-16.37 Million
2006 10.50% 6.64% 0.90x 1.76x CN¥3.71 Million
2007 11.67% 8.36% 0.96x 1.46x CN¥14.01 Million
2008 16.30% 10.30% 0.92x 1.72x CN¥58.06 Million
2009 19.59% 10.64% 1.18x 1.56x CN¥98.44 Million
2010 15.08% 10.19% 1.02x 1.45x CN¥87.99 Million
2011 12.21% 8.61% 1.02x 1.39x CN¥41.16 Million
2012 11.26% 7.06% 0.99x 1.61x CN¥25.29 Million
2013 8.28% 6.20% 0.93x 1.44x CN¥-35.68 Million
2014 12.75% 9.34% 0.85x 1.60x CN¥57.12 Million
2015 15.59% 14.13% 0.97x 1.14x CN¥131.58 Million
2016 14.52% 24.53% 0.50x 1.17x CN¥118.21 Million
2017 14.33% 23.92% 0.52x 1.15x CN¥126.28 Million
2018 14.45% 26.79% 0.46x 1.17x CN¥144.92 Million
2019 13.02% 18.93% 0.51x 1.34x CN¥107.53 Million
2020 12.22% 19.40% 0.50x 1.27x CN¥86.05 Million
2021 12.63% 17.60% 0.48x 1.50x CN¥105.38 Million
2022 15.38% 15.40% 0.62x 1.60x CN¥209.14 Million
2023 18.76% 15.78% 0.74x 1.60x CN¥335.51 Million
2024 20.40% 17.77% 0.68x 1.68x CN¥401.91 Million

Industry Comparison

This section compares Jiangzhong Pharmaceutical Co Ltd's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.

Industry Context

  • Industry: Drug Manufacturers - Specialty & Generic
  • Average net assets among peers: $2,123,990,643
  • Average return on equity (ROE) among peers: -0.22%

Peer Company Comparison

Company Net Assets Return on Equity Debt-to-Equity Market Cap
Jiangzhong Pharmaceutical Co Ltd (600750) CN¥4.45 Billion 59.03% 0.55x $1.21 Billion
Shenzhen Neptunus Bioengineering Co Ltd (000078) $6.47 Billion 9.88% 3.77x $616.08 Million
Anhui Fengyuan Pharmaceutical Co Ltd (000153) $1.18 Billion 2.74% 0.95x $320.56 Million
Shan Dong Dong-E E-Jiao Co Ltd (000423) $10.33 Billion 15.07% 0.27x $3.03 Billion
Wedge Industrial Co Ltd (000534) $298.72 Million 1.96% 0.38x $1.77 Billion
Yunnan Baiyao Group Co Ltd (000538) $35.11 Million 18.13% 0.80x $5.62 Billion
Hainan Haiyao Co Ltd (000566) $353.98 Million -9.58% 0.80x $702.18 Million
Tus Pharmaceutical Group Co Ltd (000590) $269.51 Million -61.02% 1.05x $317.08 Million
Northeast Pharmaceutical Group Co Ltd (000597) $927.49 Million 2.65% 1.38x $425.60 Million
Jilin Aodong Pharmaceutical Group Co Ltd (000623) $1.11 Billion 7.32% 0.29x $2.05 Billion
Renhe Pharmacy Co Ltd (000650) $261.49 Million 10.60% 0.82x $777.45 Million